Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autotransplantation and Trastuzumab in Advanced Breast Cancer
NCT00006123Phase 2Withdrawn
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Jul 2000
- Primary completion
- Jul 2000
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Safety and toxicity profile. Planned start Jul 2000; status: withdrawn.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00006123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006123.